Cigna is a vertically integrated healthcare services platform trading at a “PBM-overhang” discount—upside hinges on proving its rebate-free Signature model can thrive as specialty pharmacy scales.
Overview
The Cigna Group is presented as a leading global health services organization whose economics and identity have shifted decisively toward Evernorth Health Services, with Cigna Healthcare serving as a more focused, employer-centric insurance and administrative platform. The company’s “two-platform” structure allows it to participate in high-growth, technology-enabled pharmacy services—particularly specialty pharmacy—while maintaining exposure to the more stable but heavily regulated medical benefits market. For FY2025, consolidated revenue reached $274.9B, with Evernorth contributing roughly 85% of adjusted revenues, underscoring the success of the post–Express Scripts pivot toward vertical integration. Core offerings include PBM services (Express Scripts), specialty pharmacy and complex therapy management (Accredo), clinical care solutions, and commercial/international medical plans; the Medicare Advantage business was divested in early 2025 to concentrate on higher-margin commercial opportunities. Customers span large employers, government contracts (including DoD), mid-sized businesses, unions, and individuals; internationally, the company serves ~1.7M customers, offering diversification. The differentiated value proposition is Cigna’s integrated “Lead to One” approach—combining medical, pharmacy, and behavioral data to drive clinical interventions and lower total cost of care—alongside innovation in PBM pricing with the 2026 rollout of the “Signature” rebate-free model aimed at transparency and affordability. The report frames Cigna as a scaled, data-driven healthcare services platform with improving operational efficiency and a valuation that appears to discount a severe PBM reform outcome.